M&A / Deals Zymeworks cuts deal to buy Theravance for $929m in cash PharmaphorumZymeworks has reached a deal to buy Theravance, claiming rights to COPD therapy Yupelri, sold by Viatris, which made $267m last year.Read full story pharminent June 29, 2026 (Last updated: June 29, 2026) Pharmaphorum Zymeworks has reached a deal to buy Theravance, claiming rights to COPD therapy Yupelri, sold by Viatris, which made $267m last year. Read full story Post navigation Previous: BridgeBio’s achondroplasia pill shows ‘compelling’ growth and body proportionality benefitNext: UK partners with Eli Lilly on obesity plan Related Stories M&A / Deals Exegenesis Bio and Modalis sign research deal for Duchenne therapy pharminent September 11, 2026 M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026